Apoptosis
Apoptosis inhibitors are compounds that prevent or delay the process of programmed cell death, known as apoptosis. These inhibitors are vital in studying cell survival mechanisms and are used to investigate diseases where apoptosis is dysregulated, such as cancer, neurodegenerative disorders, and autoimmune diseases. By modulating apoptosis, these inhibitors can help in the development of therapies aimed at controlling cell death. At CymitQuimica, we provide a comprehensive selection of high-quality apoptosis inhibitors to support your research in cell biology, oncology, and related fields.
Subcategories of "Apoptosis"
- ASK(9 products)
- BCL(11 products)
- Caspase(144 products)
- FOXO1(3 products)
- IAP(67 products)
- Mdm2(12 products)
- PD-1/PD-L1(139 products)
- PDK(9 products)
- PERK(27 products)
- Serine/threonin kinase(18 products)
- Survivin(14 products)
- TNF(93 products)
- c-RET(62 products)
- p53(63 products)
Show 6 more subcategories
Found 6059 products of "Apoptosis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
WK369
WK369 is an innovative small molecule inhibitor of BCL6, demonstrating remarkable bioactivity against ovarian cancer by inducing cell cycle arrest and triggering apoptosis. It binds directly to the BCL6-BTB domain, obstructing the interaction between BCL6 and SMRT, which results in the reactivation of p53, ATR, and CDKN1A.Formula:C19H20FN5O2Molecular weight:369.1601NAE-IN-1
NAE-IN-1 (compound X-10) is a potent inhibitor of NAE1. It induces apoptosis and causes cell cycle arrest in the G2/M phase. Furthermore, NAE-IN-1 increases ROS levels and inhibits cell migration, demonstrating antiproliferative activity.Formula:C29H30N4O2SMolecular weight:498.20895RIPK1-IN-22
RIPK1-IN-13 (compound 28) is a selective inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1), showing a pKi of 7.66 as measured by the ADP-Glo kinase assay. It exhibits inhibitory effects in human leukemia U937 cells with a pIC50 of 7.2.Formula:C22H22N4O3SMolecular weight:422.14126Ru-Poma
<p>Ru-Poma is an Ru(II)-based photosensitizer designed to enhance the efficacy of photodynamic therapy (PDT) against tumors resistant to Cisplatin. It targets Pomalidomide to partially degrade CRBN, inducing ferroptosis by increasing lipid peroxides and downregulating GPX4 and GAPDH expression. In A549 cells, Ru-Poma exhibits cytotoxicity with IC50 values of 18.46 μM in the dark and 0.37 μM under illumination.</p>Formula:C89H75Cl2N11O11Ru·7H2OS2/IAPinh
S2/IAPinh is a conjugate composed of an inhibitor of apoptosis proteins inhibitor (IAPinh) and a ligand of sigma 2 SW43. It demonstrates anti-proliferative and apoptosis-inducing activity by degrading inhibitor of apoptosis proteins (clAP-1).Formula:C52H75Cl2FN6O6SMolecular weight:1000.48299155H1
155H1 (Compound 11) is a stapled peptide that covalently binds to hMcl1 (172-323) with an IC50 of 18 nM.Formula:C79H120FN19O23SMolecular weight:1753.85092CDD-2807
CDD-2807 is a serine/threonine kinase 33 (STK33) inhibitor with an IC50 of 9.2 nM. In mice, CDD-2807 demonstrates no significant toxicity and can cross the blood-testis barrier without accumulating in the brain. It offers reversible contraceptive effects, indicating potential for development as a male contraceptive.Formula:C29H26N4OMolecular weight:446.21066MD-265
CAS:MD-265 is a PROTAC degrader that targets and degrades MDM2, leading to the activation of p53 in cancer cells with wild-type p53. MD-265 achieves complete tumor regression and enhances long-term survival in leukemic mice.Formula:C50H51Cl2FN6O6Molecular weight:921.88PL120131
PL120131 is a PD-1/PD-L1 inhibitory peptide that disrupts the interaction between PD-1 and PD-L1 by binding to PD-1. This compound can inhibit the apoptosis signaling pathway mediated by PD-1, thereby preventing apoptosis (apoptosis) in Jurkat cells and primary lymphocytes. Additionally, PL120131 supports cytotoxic T lymphocytes (CTL) in exhibiting antitumor activity.Formula:C62H105N19O18Color and Shape:SolidMolecular weight:1404.61RIP1 kinase inhibitor 9
RIP1 kinase inhibitor 9 (compound SY-1) is a selective inhibitor of RIP kinase. It effectively reduces central inflammatory responses caused by seizures. RIP1 kinase inhibitor 9 also obstructs Z-VAD-FMK-induced necroptosis in HT-29 cells, with an EC50 of 7.04 nM.Formula:C25H21N3O3Molecular weight:411.15829PROTAC PD-L1 degrader-1
PROTACPD-L1 degrader-1 is a CRBN-based PD-L1-PROTAC degrader with significant PD-L1 protein degradation capacity. It demonstrates strong PD-L1 degradation activity in 4T1 cells, with a DC50 of 0.609 μM. This compound is applicable to breast cancer research.Bcl-2-IN-21
Bcl-2-IN-21 (compound C1), an iridium-based anticancer agent, effectively targets and inhibits Bcl-2, thereby impeding cancer cell colony formation and promoting increased levels of Bax and caspase 3.Formula:C45H33F6IrN5PMolecular weight:980.96Anticancer agent 204
Anticanceragent 204 (Compound 6) is a fluorinated derivative of cinnamamides with anticancer activity. It can arrest the cell cycle of HepG2 cells in the G1 phase and induces apoptosis by reducing mitochondrial membrane polarization (MMP) levels.Formula:C26H18FN5O3SMolecular weight:499.11144Antitumor agent-170
Antitumor agent-170 (Compound C6) inhibits PD-1/PD-L1 interaction and PARP7 with IC50 values of 0.342 μM and 7.05 nM, respectively. It shows high affinity for human PD-L1, with a Ki of 9.31 nM, and can restore T cell function while increasing IFN-γ secretion. In mouse models, Antitumor agent-170 exhibits antitumor effects against melanoma and demonstrates favorable pharmacokinetic properties.Formula:C59H69ClF3N11O9Molecular weight:1167.49204PRDX1-IN-2
PRDX1-IN-2 (compound 15) is a selective inhibitor of the antioxidant enzyme Peroxiredoxin 1 (PRDX1) with an IC50 of 0.35 μM. It reduces mitochondrial membrane potential in SW620 cells, potentially due to increased ROS resulting from PRDX1 inhibition, leading to apoptosis. PRDX1-IN-2 is applicable in colorectal cancer research.NCA029
NCA029 is a potent activator of human caseinolytic protease P (HsClpP) with an EC50 of 0.15 μM. It targets HsClpPP and triggers an ATF3-dependent integrated stress response, resulting in the death of colon cancer cells.Formula:C22H20F3N3OMolecular weight:399.15585EGFR-IN-107
<p>EGFR-IN-107 (compound 3r) is an orally active EGFR inhibitor with IC50 values of 0.4333 μM for EGFRWT and 0.0438 μM for EGFRL858R/T790M. It exhibits antiproliferative activity, effectively inhibiting the proliferation of H1975 cells and inducing apoptosis (apoptosis). EGFR-IN-107 is applicable in cancer research.</p>Formula:C34H36FN7O2Molecular weight:593.29145RIPK3-IN-3
RIPK3-IN-3 (compound 20) is a selective RIPK3 inhibitor that demonstrates potent activity with an IC50 value of 10 nM.Formula:C16H11N5SColor and Shape:SolidMolecular weight:305.36Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride
CAS:Thalidomide-based E3 ligase ligand with PEG2-C2 linker; used as an immunomodulatory cancer treatment.Formula:C21H27ClN4O8Purity:98.09%Color and Shape:SolidMolecular weight:498.914MAO-B-IN-30
CAS:MAO-B-IN-30 is a selective and potent MAO-B inhibitor that crosses the blood-brain barrier with antiproliferative activity and inhibits both MAO-A and MAO-B.MAO-B-IN-30 reduces the levels of TNF-alpha, IL-6, and NF-kB in organisms, and can be used to study Parkinson's-type neurological disorders.Formula:C15H10BrN3O2Purity:98.31%Color and Shape:SoildMolecular weight:344.16
